CD274 and neoplasm: ORR was achieved regardless of tumor PD-L1 expression and the respective ORRs were 33%, 47%, 47%, and 43% for Nivolumab (10 mg/kg) with gemcitabine/cisplatin, Nivolumab (10 mg/kg) along with pemetrexed/cisplatin, Nivolumab (10 mg/kg) in combination with paclitaxel/carboplatin, and Nivolumab (5 mg/kg) plus paclitaxel/carboplatin in this study.